Coronavirus Update: Moderna Set For Bigger Test As Vaccine Trials Begin In Older People
Plus: Inhaled Remdesivir Trials, Clover Gets More Funding
Moderna's vaccine has shown encouraging early results in younger adults, but over-55s and over-70s cohorts represent a bigger safety and efficacy hurdle.
You may also be interested in...
Operation Warp Speed extends its funding beyond vaccines into antibodies, while insiders say friction between Moderna and US government scientists has caused delays.
Europe has granted a conditional approval to Gilead’s drug, now named Veklury, costing €2,000 per treatment.
Clover enters the clinical trial stage in race to develop a vaccine, while the UK moves to protect a range of key industries from foreign takeover, including vaccines manufacturers. Meanwhile, confirmed cases in Beijing continue to rise.